Effect of rituximab on human in vivo antibody immune responses.

[1]  S. Agarwal,et al.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. , 2010, Arthritis and rheumatism.

[2]  Darrell M. Wilson,et al.  Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. , 2009, The New England journal of medicine.

[3]  H. Kolb,et al.  Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes , 2008, Diabetes Care.

[4]  W. Grossman,et al.  Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias , 2008, Pediatric blood & cancer.

[5]  Thomas F. Tedder,et al.  Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice1 , 2008, The Journal of Immunology.

[6]  Nichole E Carlson,et al.  Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.

[7]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. , 2006, Arthritis and rheumatism.

[8]  F. Stevenson,et al.  Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine specific. , 2006, Blood.

[9]  L. Diehl,et al.  Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1 , 2005, The Journal of Immunology.

[10]  H. Ochs,et al.  Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  N. Fineberg,et al.  Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.

[12]  S. Horning,et al.  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. , 2004, Blood.

[13]  M. Pescovitz,et al.  In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. , 2004, Human antibodies.

[14]  H. Handsfield,et al.  Abnormal antibody responses in patients with persistent generalized lymphadenopathy , 2004, Journal of Clinical Immunology.

[15]  M. Cooper,et al.  Primary immunodeficiencies. , 2003, American family physician.

[16]  Antonio Lanzavecchia,et al.  Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells , 2002, Science.

[17]  J. Baars,et al.  Rituximab treatment results in impaired secondary humoral immune responsiveness. , 2002, Blood.

[18]  M. Eibl,et al.  Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. , 2002, Clinical immunology.

[19]  G. Gonzalez-Stawinski,et al.  Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). , 2001, Clinical immunology.

[20]  H. Ochs,et al.  Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. , 2000, The Journal of infectious diseases.

[21]  H. Ochs,et al.  Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage ΦX174 in asymptomatic HIV-1 infected patients , 2000, AIDS.

[22]  M. Lebwohl,et al.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. , 1999, The Journal of clinical investigation.

[23]  H. Ochs,et al.  Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. , 1998, Blood.

[24]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[25]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Narabayashi,et al.  Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.

[28]  R. Kobayashi,et al.  Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. , 1992, Blood.

[29]  C. Kunz,et al.  Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. , 1990, Vaccine.

[30]  H. Ochs,et al.  Defective humoral immunity in pediatric acquired immune deficiency syndrome. , 1985, The Journal of pediatrics.

[31]  H. Deeg,et al.  Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. , 1982, Transplantation.

[32]  L. Harker,et al.  The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets , 1980 .

[33]  H. Ochs,et al.  The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. , 1980, Blood.

[34]  H. Ochs,et al.  The recognition and classification of immunodeficiency diseases with bacteriophage phiChi 174. , 1975, Birth defects original article series.

[35]  H. Ochs,et al.  STUDIES OF IMMUNOLOGICAL REACTIVITY FOLLOWING SYNGENEIC OR ALLOGENEIC MARROW GRAFTS IN MAN , 1973, Transplantation.

[36]  H. Ochs,et al.  Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. , 1971, The Journal of clinical investigation.

[37]  H. Kunkel,et al.  PRIMARY IMMUNODEFICIENCIES , 1971, Pediatrics.